Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Undiluted I.V.-Hepabig in Post-liver Transplant Patients
NCT05686759Phase 3Recruiting
- Sponsor
- GC Biopharma Corp
- Start
- Apr 2023
- Primary completion
- Jun 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of GC5103 in hepatitis B (HBV), sponsored by GC Biopharma Corp. Started Apr 2023; status: recruiting.
02
Drugs
GC5103
03
Conditions
hepatitis B (HBV)
Beyond the preview
Go deeper on NCT05686759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05686759.